Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo

Griffithsin (GRFT) is a broad-spectrum antiviral protein that is effective against several glycosylated viruses. Here, we have evaluated the in vitro and in vivo antiviral activities of GRFT against Japanese encephalitis virus (JEV) infection. In vitro experiments showed that treatment of JEV with G...

Full description

Saved in:
Bibliographic Details
Published in:Archives of virology 2013-02, Vol.158 (2), p.349-358
Main Authors: Ishag, Hassan Z. A., Li, Chen, Huang, Li, Sun, Ming-xia, Wang, Fengjuan, Ni, Bo, Malik, Thowaiba, Chen, Pu-yan, Mao, Xiang
Format: Article
Language:English
Subjects:
Animals
Antiviral Agents - pharmacology
Biomedical and Life Sciences
Biomedicine
Cell Line
Chromatography
Cricetinae
Cytotoxicity
Disease Models, Animal
E coli
Encephalitis
Encephalitis Virus, Japanese - drug effects
Encephalitis Virus, Japanese - pathogenicity
Encephalitis, Japanese - prevention & control
Enzymes
Flavivirus
Glycoproteins
Infections
Infectious Diseases
Japanese encephalitis virus
Medical Microbiology
Mice
Mice, Inbred BALB C
Monoclonal antibodies
Original
Original Article
Plant Lectins - pharmacology
Polyclonal antibodies
Proteins
Survival Analysis
Veterinary medicine
Virology
Virus Internalization - drug effects
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Griffithsin (GRFT) is a broad-spectrum antiviral protein that is effective against several glycosylated viruses. Here, we have evaluated the in vitro and in vivo antiviral activities of GRFT against Japanese encephalitis virus (JEV) infection. In vitro experiments showed that treatment of JEV with GRFT before inoculation of BHK-21 cells inhibited infection in a dose-dependent manner, with 99 % inhibition at 100 μg/ml and a 50 % inhibitory concentration ( IC 50 ) of 265 ng/ml (20 nM). Binding assays suggested that binding of GRFT to JEV virions inhibited JEV infection. In vivo experiment showed that GRFT (5 mg/kg) administered intraperitoneally before virus infection could completely prevent mortality in mice challenged intraperitoneally with a lethal dose of JEV. Our study also suggested that GRFT prevents JEV infection at the entry phase by targeting the virus. Collectively, our data demonstrate that GRFT is an antiviral agent with potential application in the development of therapeutics against JEV or other flavivirus infections.
ISSN:0304-8608
1432-8798
DOI:10.1007/s00705-012-1489-2